Integration of SARS-CoV-2 testing and genomic sequencing into influenza sentinel surveillance in Uganda, January to December 2022
Microbiology Spectrum · 2023
DOI: 10.1128/spectrum.01328-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2023. Verfasst von John T Kayiwa und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Arbovirology, Emerging and Re-emerging Viral Diseases, Uganda Virus Research Institute , Entebbe, Uganda. Hauptthemen laut MEDLINE: Influenza, Human, COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCIRD CDC HHS, Medical Research Council, CARES Foundation.
Abstract (Originalsprache)
The Uganda Virus Research Institute, National Influenza Center laboratory integrated SARS-CoV-2 polymerase chain reaction testing and genomic sequencing into the influenza surveillance program that was established in 2007. A total of 7,698 nasopharyngeal/oropharyngeal (NP/OP) swab samples were collected and analyzed from ILI/SARI sentinel sites across the country from January to December 2022. All samples were tested for influenza and SARS-CoV-2. Of these, 252 (3.3%), 162 (2.1%), and 589 (7.7%) were positive for influenza A, influenza B, and SARS-CoV-2, respectively. Out of 414 influenza-positive samples, 122 (29.5%) were AH1pdm09, 130 (31.4%) were AH3, and 162 (39.1%) were B-Victoria. All SARS-CoV-2 sequenced samples were of the Omicron variant, with subvariants of concern known to evade the immune system being detected, such as BQ.1 and XBB.2. Other SARS-CoV-2 positive samples collected from other health centers in the community outside the surveillance sites were included into SARS-CoV-2 genomic sequencing with similar patterns with respect to variants. In all, the ILI/SARI surveillance system has shown to be an efficient, cost-effective, and sustainable program, providing a ready platform to monitor the circulation of SARS-CoV-2 in communities at the national level while remaining vigilant for the persistent threat of influenza. The integration of SARS-CoV-2 detection and genomic surveillance into the influenza surveillance program will strengthen the laboratory response capacity, as well as facilitate the timely release of SARS-CoV-2 genomic information to be used to complement the multiple response strategies for COVID-19 pandemic mitigation. IMPORTANCE Respiratory pathogens cause high rates of morbidity and mortality globally and have high pandemic potential. During the SARS-CoV-2 pandemic, influenza surveillance was significantly interrupted because of resources being diverted to SARS-CoV-2 testing and sequencing. Based on recommendations from the World Health Organization, the Uganda Virus Research Institute, National Influenza Center laboratory integrated SARS-CoV-2 testing and genomic sequencing into the influenza surveillance program. We describe the results of influenza and SARS-CoV-2 testing of samples collected from 16 sentinel surveillance sites located throughout Uganda as well as SARS-CoV-2 testing and sequencing in other health centers. The surveillance system showed that both SARS-CoV-2 and influenza can be monitored in communities at the national level. The integration of SARS-CoV-2 detection and genomic surveillance into the influenza surveillance program will help facilitate the timely release of SARS-CoV-2 information for COVID-19 pandemic mitigation and provide important information regarding the persistent threat of influenza.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Arbovirology, Emerging and Re-emerging Viral Diseases, Uganda Virus Research Institute , Entebbe, Uganda.
- Genomics and Bioanalytics, Los Alamos National Laboratory , Los Alamos, New Mexico, USA.
- Medical Research Council/Uganda Virus Research Institute & London School of Hygiene & Tropical Medicine, Uganda Research Unit , Entebbe, Uganda.
ORCID-Profile: John T Kayiwa, Andrew William Bartlow
Förderung
- NCIRD CDC HHS
- Medical Research Council
- CARES Foundation
- HHS | Centers for Disease Control and Prevention
Zitieren
APA
Kayiwa, J. T., Nassuna, C., Mulei, S., Kiggundu, G., Nakaseegu, J., Nabbuto, M., Amwine, E., Nakamoga, B., Nankinga, S., Atuhaire, P., Nabiryo, P., Alunzi, P., Mbaziira, T., Isabirye, P., Ayuro, N., Owor, N., Kiconco, J., Bakamutumaho, B., Middlebrook, E. A., …, & Bartlow, A. W. (2023). Integration of SARS-CoV-2 testing and genomic sequencing into influenza sentinel surveillance in Uganda, January to December 2022. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01328-23
Vancouver
Kayiwa JT, Nassuna C, Mulei S, Kiggundu G, Nakaseegu J, Nabbuto M, et al. Integration of SARS-CoV-2 testing and genomic sequencing into influenza sentinel surveillance in Uganda, January to December 2022. Microbiology Spectrum. 2023. doi:10.1128/spectrum.01328-23
BibTeX
@article{Kayiwa2023,
author = {Kayiwa, John T and Nassuna, Charity and Mulei, Sophia and Kiggundu, Gladys and Nakaseegu, Joweria and Nabbuto, Maria and Amwine, Esther and Nakamoga, Bridget and Nankinga, Sarah and Atuhaire, Phiona and Nabiryo, Pheobe and Alunzi, Pixy and Mbaziira, Tony and Isabirye, Paul and Ayuro, Noel and Owor, Nicholas and Kiconco, Jocelyn and Bakamutumaho, Barnabas and Middlebrook, Earl Austin and Kaleebu, Pontiano and Lutwama, Julius J and Bartlow, Andrew William},
title = {Integration of SARS-CoV-2 testing and genomic sequencing into influenza sentinel surveillance in Uganda, January to December 2022},
journal = {Microbiology Spectrum},
year = {2023},
doi = {10.1128/spectrum.01328-23}
}
EUVIMED